Recurrent Primary Peritoneal Clear Cell Adenocarcinoma Clinical Trials in Buffalo, New York

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer